BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27332908)

  • 1. Fine-Tuning the Treatment of Hodgkin's Lymphoma.
    Bartlett NL
    N Engl J Med; 2016 Jun; 374(25):2490-2. PubMed ID: 27332908
    [No Abstract]   [Full Text] [Related]  

  • 2. Classical Hodgkin's lymphoma associated with Langerhans cell histiocytosis: multiagent chemotherapy resulted in histologic resolution of both the classical Hodgkin's lymphoma and Langerhans cell proliferation components.
    Greaves WO; Bueso-Ramos C; Fayad L
    J Clin Oncol; 2011 Feb; 29(4):e76-8. PubMed ID: 21041711
    [No Abstract]   [Full Text] [Related]  

  • 3. [Sarcoidosis-like reaction after treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in a patient with Hodgkin's lymphoma].
    Torrent A; Navarro JT; Andreo FC; Ribera JM
    Med Clin (Barc); 2013 Aug; 141(3):134-5. PubMed ID: 23332624
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in the treatment of early-stage Hodgkin's lymphoma.
    Longo DL; Armitage JO
    N Engl J Med; 2015 Apr; 372(17):1667-9. PubMed ID: 25901431
    [No Abstract]   [Full Text] [Related]  

  • 6. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using PET-CT to tailor treatment for Hodgkin's lymphoma.
    Tanday S
    Lancet Oncol; 2016 Aug; 17(8):e322. PubMed ID: 27345638
    [No Abstract]   [Full Text] [Related]  

  • 8. Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.
    Honda A; Nakamura F; Nannya Y; Shintani Y; Fukayama M; Ichikawa M; Kurokawa M
    Ann Hematol; 2014 Jun; 93(6):1073-4. PubMed ID: 24173088
    [No Abstract]   [Full Text] [Related]  

  • 9. Escalated BEACOPP in advanced Hodgkin's lymphoma.
    Casasnovas O; Coiffier B
    Lancet; 2012 May; 379(9828):1767-8. PubMed ID: 22480757
    [No Abstract]   [Full Text] [Related]  

  • 10. Uncommon presentations of Hodgkin's disease. Case 2. Hodgkin's disease of the nasopharynx.
    Hollander SL
    J Clin Oncol; 2004 Jan; 22(1):195-6. PubMed ID: 14701783
    [No Abstract]   [Full Text] [Related]  

  • 11. Presentation of Hodgkin's lymphoma with Ophelia syndrome.
    Olmos D; Rueda A; Jurado JM; Alba E
    J Clin Oncol; 2007 May; 25(13):1802-3. PubMed ID: 17470872
    [No Abstract]   [Full Text] [Related]  

  • 12. Pericardial effusion due to pericardium involvement by Hodgkin's lymphoma.
    Guastafierro S; Cappabianca S; Falcone U
    Ann Hematol; 2013 Jun; 92(6):853-4. PubMed ID: 23196418
    [No Abstract]   [Full Text] [Related]  

  • 13. Hodgkin's lymphoma: better outcomes with fewer drugs?
    Casasnovas O; Coiffier B
    Lancet; 2015 Apr; 385(9976):1371-3. PubMed ID: 25539731
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of advanced, resistant Hodgkin's disease and non-Hodgkin's lymphoma: a phase II study.
    Williams SF; Ultmann JE; Gaynor E; Watson S
    Cancer Treat Rep; 1986 Aug; 70(8):1033-4. PubMed ID: 2425964
    [No Abstract]   [Full Text] [Related]  

  • 15. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical case of the month. The association of Hodgkin's disease and nephrotic syndrome].
    Baron F; Hermanne JP; Fassotte MF; Beguin Y; Fillet G
    Rev Med Liege; 1998 Nov; 53(11):651-3. PubMed ID: 9887654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in the chemotherapy of malignant lymphoma 1. Chemotherapy of Hodgkin's disease].
    Suon SZ
    Zhonghua Nei Ke Za Zhi; 1985 Feb; 24(2):117-120, contd. PubMed ID: 2580675
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of outcomes in studies of advanced Hodgkin's lymphoma.
    Johnson PW; Radford JA; Cullen MH; Sydes MR; Stenning SP; Hancock BW
    J Clin Oncol; 2006 Jul; 24(20):3309; author reply 3309-10. PubMed ID: 16829655
    [No Abstract]   [Full Text] [Related]  

  • 19. Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma.
    Ypma PF; Wijermans PW; Koppen H; Sillevis Smitt PA
    Neth J Med; 2006; 64(7):243-7. PubMed ID: 16929086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET-Directed Therapy for Hodgkin's Lymphoma.
    Bishop G
    N Engl J Med; 2015 Jul; 373(4):392. PubMed ID: 26200988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.